CCK-8 assay findings showed that tumor-specific antibody T-mab could obviously decrease cell viabilities of NCIN87 cells (p < 0.001) and NCIN87-DR cells (p < 0.05) compared to those cells without T-mab treatments, at 24 h, 48 h, and 72 h post cell culture (Figure 4B). Here, TBXT is linked to neoplasm.